Krystal Biotech (KRYS) Income from Continuing Operations (2016 - 2026)
Krystal Biotech recorded quarterly Income from Continuing Operations of 55932000.0 in Q1 2026, up 8.82% quarter-over-quarter from 51400000.0 in Q4 2025, and up 56.53% year-over-year from 35733000.0 in Q1 2025.
Krystal Biotech's Income from Continuing Operations history runs 11 years deep, the most recent figure standing at 55932000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 56.53% year-over-year to 55932000.0; the TTM figure through Mar 2026 stood at 225072000.0 (up 81.52% YoY), while the FY2025 annual figure was 204831000.0, up 129.74% from the prior year.
- Income from Continuing Operations came in at 55932000.0 for Q1 2026 at Krystal Biotech, up from 51400000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 80747000.0 in Q3 2023 to a low of 49965000.0 in Q1 2022.
- A 5-year average of 12997352.94 and a median of 15568000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations plunged 215.99% in 2022 and jumped 3734.01% in 2025, its largest moves.
- Krystal Biotech's Income from Continuing Operations stood at 32052000.0 in 2022, then jumped by 127.12% to 8692000.0 in 2023, then surged by 423.62% to 45513000.0 in 2024, then gained by 12.93% to 51400000.0 in 2025, then climbed by 8.82% to 55932000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 55932000.0, 51400000.0, and 79365000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Krystal Biotech | 9.05 Bn | 8.23 Bn | 110.03 Mn | 55.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 55.93 Mn |
| Dec 31, 2025 | 51.40 Mn |
| Sep 30, 2025 | 79.37 Mn |
| Jun 30, 2025 | 38.38 Mn |
| Mar 31, 2025 | 35.73 Mn |
| Dec 31, 2024 | 45.51 Mn |
| Sep 30, 2024 | 27.18 Mn |
| Jun 30, 2024 | 15.57 Mn |
| Mar 31, 2024 | 932,000.00 |
| Dec 31, 2023 | 8.69 Mn |
| Sep 30, 2023 | 80.75 Mn |
| Jun 30, 2023 | -33.21 Mn |
| Mar 31, 2023 | -45.30 Mn |
| Dec 31, 2022 | -32.05 Mn |
| Sep 30, 2022 | -29.85 Mn |
| Jun 30, 2022 | -28.11 Mn |
| Mar 31, 2022 | -49.97 Mn |
| Dec 31, 2021 | -21.81 Mn |
| Sep 30, 2021 | -15.59 Mn |
| Jun 30, 2021 | -16.36 Mn |
| Mar 31, 2021 | -15.81 Mn |
| Dec 31, 2020 | -10.38 Mn |
| Sep 30, 2020 | -9.61 Mn |
| Jun 30, 2020 | -6.83 Mn |
| Mar 31, 2020 | -5.34 Mn |
| Dec 31, 2019 | -5.36 Mn |
| Sep 30, 2019 | -4.27 Mn |
| Jun 30, 2019 | -5.35 Mn |
| Mar 31, 2019 | -4.11 Mn |
| Dec 31, 2018 | -3.71 Mn |
| Sep 30, 2018 | -2.76 Mn |
| Jun 30, 2018 | -2.28 Mn |
| Mar 31, 2018 | -2.15 Mn |
| Dec 31, 2017 | -1.39 Mn |
| Sep 30, 2017 | -5.27 Mn |
| Jun 30, 2017 | -759,000.00 |
| Mar 31, 2017 | -494,000.00 |
| Dec 31, 2016 | -620,000.00 |
| Sep 30, 2016 | -322,000.00 |